Dynamic Technology Lab Private Ltd Makes New $215,000 Investment in Supernus Pharmaceuticals, Inc. $SUPN

Dynamic Technology Lab Private Ltd bought a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 6,810 shares of the specialty pharmaceutical company’s stock, valued at approximately $215,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Caitong International Asset Management Co. Ltd bought a new stake in shares of Supernus Pharmaceuticals during the 1st quarter worth approximately $41,000. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in Supernus Pharmaceuticals in the first quarter worth $46,000. GAMMA Investing LLC increased its stake in Supernus Pharmaceuticals by 116.7% in the second quarter. GAMMA Investing LLC now owns 2,861 shares of the specialty pharmaceutical company’s stock worth $90,000 after purchasing an additional 1,541 shares during the period. CWM LLC lifted its position in shares of Supernus Pharmaceuticals by 92.4% during the second quarter. CWM LLC now owns 3,080 shares of the specialty pharmaceutical company’s stock worth $97,000 after purchasing an additional 1,479 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new stake in shares of Supernus Pharmaceuticals during the first quarter valued at $103,000.

Supernus Pharmaceuticals Stock Up 0.4%

Shares of NASDAQ:SUPN opened at $46.26 on Thursday. The firm has a 50 day moving average of $48.59 and a 200 day moving average of $40.73. The company has a market capitalization of $2.65 billion, a price-to-earnings ratio of 40.23 and a beta of 0.75. Supernus Pharmaceuticals, Inc. has a 52 week low of $29.16 and a 52 week high of $57.65.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.36). The company had revenue of $170.00 million during the quarter, compared to analysts’ expectations of $175.82 million. Supernus Pharmaceuticals had a net margin of 9.70% and a return on equity of 14.22%. The company’s revenue was up 9.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.69 earnings per share. Supernus Pharmaceuticals has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Supernus Pharmaceuticals, Inc. will post 2.38 EPS for the current year.

Insider Activity

In related news, SVP Frank Mottola sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $45.87, for a total transaction of $229,350.00. Following the completion of the transaction, the senior vice president owned 15,496 shares in the company, valued at $710,801.52. The trade was a 24.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Jack A. Khattar sold 59,900 shares of the stock in a transaction that occurred on Thursday, October 9th. The shares were sold at an average price of $50.57, for a total transaction of $3,029,143.00. Following the sale, the chief executive officer directly owned 1,206,578 shares of the company’s stock, valued at $61,016,649.46. The trade was a 4.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 183,135 shares of company stock valued at $8,773,587. Insiders own 8.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on SUPN shares. Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Tuesday. Piper Sandler upgraded Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $40.00 to $65.00 in a report on Thursday, October 9th. Bank of America began coverage on Supernus Pharmaceuticals in a report on Wednesday, October 29th. They set a “buy” rating and a $65.00 price objective on the stock. Finally, Cantor Fitzgerald lifted their target price on Supernus Pharmaceuticals from $46.00 to $63.00 and gave the company an “overweight” rating in a research report on Tuesday, September 30th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $63.25.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.